Literature DB >> 33469184

The TGF-β1 pathway is early involved in neurogenic bladder fibrosis of juvenile rats.

Yan Chen1,2, Yuan Ma1,2, Yulin He1,2, Dong Xing1,2, Erpeng Liu1,2, Xinghuan Yang1,2, Wen Zhu3, Qingwei Wang3, Jian Guo Wen4,5.   

Abstract

BACKGROUND: This study investigated whole neurogenic bladder's progression changes, as well as the expression of TGF-β1 fibrosis pathway-related proteins in bilateral spinal nerve-amputated juvenile rats.
METHODS: Sixty-four 8-week-old rats (32 bilateral L6 + S1 spinal nerve amputated and 32 sham operated) were selected. Cystometry was performed. General assessments, Masson, Sirius red, immunohistochemical staining, and western blotting of fibrosis and TGF-β1 pathway-related proteins were conducted using bladder tissues.
RESULTS: Cystometry results showed that the basal intravesical pressures and bladder capacities in nerve-amputated rats were significantly higher than those in sham-operated ones. Compared to the sham-operated groups, the bladder size and wall thickness in the nerve-amputated groups increased initially but then decreased over time. However, bladder weight continuously increased over time. Disintegration, thickening, and hypertrophy of the bladder wall were found over time in the amputated rats. Moreover, there was a significant increase in collagen III, and the ratio of collagen III/I was higher in amputated rats (P < 0.01). Finally, the expression of TGF-β1, TGF-βRI, Smad2, and collagen III and I increased in amputated bladder tissues, while Smad6 decreased over time.
CONCLUSIONS: The main clinical features of pediatric neurogenic bladder (PNB) were detrusor paralysis and continuous intravesical pressure. Biological molecular findings are earlier than the pathophysiological findings. Therefore, early preventing bladder fibrosis by targeting TGF-β1/Smad pathway-related proteins once knowing the PNB diagnosis might be an alternative treatment for PNB. IMPACT: The study found that the main clinical features of PNB were detrusor paralysis, continuous intravesical pressure, and increased TGF-beta/Smad signal proteins over time. The study makes contributions to the literature because it suggests biological molecular findings are earlier than the pathophysiological findings by various staining in PNB. The study investigated whole neurogenic bladder's progression changes, as well as the expression of TGF-β1 fibrosis pathway-related proteins in the spinal nerve-injured PNB juvenile rat models, which suggests that early prevention of bladder fibrosis by targeting TGF-β1/Smad pathway-related proteins once knowing the PNB diagnosis might be an alternative treatment for pediatric neurogenic bladder.
© 2021. The Author(s), under exclusive licence to the International Pediatric Research Foundation, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33469184     DOI: 10.1038/s41390-020-01329-x

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  1 in total

1.  The protective role of Schwann cells in bladder smooth muscle cell fibrosis.

Authors:  Qian Liu; Ruoyi Wang; Chuntian Wang; Yanan Li; Aiwu Li
Journal:  Int J Clin Exp Pathol       Date:  2019-10-01
  1 in total
  3 in total

1.  Activation of the TGF-β1/Smads/α-SMA pathway is related to histological and functional changes in children with neurogenic bladder.

Authors:  Xinghuan Yang; Qingsong Pu; Yibo Wen; Yi Zhao; Junkui Wang; Pengchao Xu; Yuan Ma; Erpeng Liu; Lei Lv; Jian Guo Wen
Journal:  Sci Rep       Date:  2022-06-03       Impact factor: 4.996

2.  Urinary exosomal vitronectin predicts vesicoureteral reflux in patients with neurogenic bladders and spinal cord injuries.

Authors:  Jue Li; Shiying Cai; Chunxian Zeng; Ling Chen; Chun Zhao; Ying Huang; Wenzhi Cai
Journal:  Exp Ther Med       Date:  2021-11-23       Impact factor: 2.447

3.  Telmisartan inhibits bladder smooth muscle fibrosis in neurogenic bladder rats.

Authors:  Qian Liu; Ruoyi Wang; Nan Ma; Chuntian Wang; Weixiu Chen
Journal:  Exp Ther Med       Date:  2022-01-11       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.